Malignant melanoma: treatments emerging, but early detection is still key.
Although we are beginning to develop treatment options for malignant melanoma, earlier recognition of potential primary melanomas remains the most effective way to increase survival in this highly malignant disease. This article reviews prominent risk factors for melanoma, key physical findings in at-risk patients, new melanoma staging guidelines, and recent and emerging therapy options.
Department of Hematology/Oncology and Center for Cancer Drug Discovery and Development, The Cleveland Clinic Foundation, OH 44195, USA.
Paul
P
Masci
Ernest C
EC
Borden
D000328:Adult; D004416:Dysplastic Nevus Syndrome / Q000175:diagnosis; D005260:Female; D006370:Heliotherapy / Q000009:adverse effects; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D009367:Neoplasm Staging; D011230:Precancerous Conditions / Q000175:diagnosis; D011994:Recombinant Proteins; D012307:Risk Factors; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D014466:Ultraviolet Rays / Q000009:adverse effects
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins